E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
advanced epithelial ovarian cancer |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10066697 |
E.1.2 | Term | Ovarian cancer recurrent |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this study is to determine the safety and efficacy of intravenous karenitecin versus topotecan in patients with platinum/taxane-resistant advanced epithelial ovarian cancer. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
A PHASE 3 STUDY OF SAFETY AND EFFICACY OF KARENITECIN VERSUS TOPOTECAN ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER; AMENDMENT 1 DATE: 17 MAY 2007. This is the same protocol title as for the main study. There is not a second study title associated with this study. In addition to the previously stated primary and secondary endpoints for the main study, the sub-study will include evaluation of Karenitecin PK and assessment of the ECG for potential effect on cardiac repolarization. |
|
E.3 | Principal inclusion criteria |
1. Age ≥ 18 years. 2. Documented histopathological or cytological diagnosis of stage III or IV epithelial ovarian cancer as defined by the International Federation of Gynecology and Obstetrics (FIGO) (Appendix D of the protocol). 3. The following tumor histological epithelial cell types will be accepted: • Serous adenocarcinoma • Endometrioid adenocarcinoma • Mucinous adenocarcinoma • Undifferentiated carcinoma • Clear cell adenocarcinoma • Mixed epithelial carcinoma • Transitional cell carcinoma • Adenocarcinoma (grade ≥ 2) not otherwise specified. 4. Documented resistance to platinum/taxane-based chemotherapy, as indicated by relapse/progression while on or within 6 months of completion of treatment in a first-line or second-line setting; or a best response of stable disease (SD) after 6 cycles of platinum/taxane treatment in the first-line setting. Platinum/taxane-based regimens must have included either cisplatin or carboplatin, and paclitaxel. 5. Have measurable disease, defined by the presence of at least one radiographicallyconfirmed (computed tomography[CT]/magnetic resonance imaging [MRI]) measurable lesion that can be accurately measured in at least one dimension (longest diameter [LD] to be recorded) as ≥ 20 mm with conventional techniques (CT/MRI), or ≥ 10 mm with spiral CT scan. 6. Documentation of progressive disease (PD) according to RECIST or WHO criteria following the immediate prior treatment regimen or a best response of SD after 6 cycles of platinum/taxane treatment in the first-line setting. 7. More than 3 weeks (21 days) must have elapsed since completion of the last treatment with any investigational or approved hormonal therapy, radiation, chemotherapy, or surgery, prior to randomization. 8. Have an ECOG PS ≤ 2 within 14 days before randomization. 9. Have baseline laboratory parameters within the following ranges (without need for hematopoietic growth factor use or transfusion support) within 14 days before randomization: • Absolute neutrophil count (ANC) ≥ 1.5 × 109/L • Hemoglobin ≥ 9 g/dL • Platelet count ≥ 100 × 109/L • Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) • Aspartate aminotransferase (AST/SGOT) ≤ 2 × ULN • Alanine aminotransferase (ALT/SGPT) ≤ 2 × ULN • Alkaline phosphatase ≤ 2.5 × ULN. 10. Have a calculated creatinine clearance normalized to BSA that is > 40 mL/min determined within 14 days before randomization. 11. Disease-free period of > 5 years from any previous malignancies, excluding curativelytreated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix. 12. Provide informed consent within 21 days before randomization (informed consent to be obtained prior to any screening procedures).
|
|
E.4 | Principal exclusion criteria |
1. Patients with the following tumor histological epithelial cell types will not be accepted: • Malignant Brenner or borderline tumor • Low-potential (grade 0) tumor • Squamous cell carcinoma • Granulosa theca cell tumor • Germ cell tumor • Sex cord-stromal tumor • Carcinosarcoma • Mixed Müllerian tumor • Metastatic carcinoma from other sites to ovary • Low-grade (grade 1) adenocarcinoma. 2. Have current evidence of congestive heart failure (New York Heart Association Classification Class II or greater). 3. Have a recent onset (< 6 months prior to randomization) of angina pectoris, unstable angina pectoris, uncontrolled ventricular tachycardia, myocardial infarction, stroke, or transient ischemic attacks. 4. Have recent history (within 6 months) of uncontrolled seizures. 5. Have an active infection (including viral, fungal, bacterial, rickettsial, mycobacterial, or parasitic). 6. Have uncontrolled high blood pressure, uncontrolled diabetes mellitus, or other serious underlying medical condition not compatible with study entry. 7. Received prior treatment with a camptothecin (topotecan, CPT-11, or investigational camptothecins). 8. Received prior treatment with any platinum agent other than cisplatin or carboplatin. 9. Received prior radiation therapy to greater than one-third of the hematopoietic sites (one-third of the pelvis and axial skeleton combined). 10. Concurrently receiving investigational drug therapy for cancer treatment or investigational treatment for any other indication. 11. Have a positive pregnancy test or are unwilling to practice an effective contraceptive method during study (premenopausal patients). 12. Are breast feeding. 13. Have a life expectancy < 3 months. 14. Are judged by the Investigator to be unlikely to be able to fully comply with the study protocol and/or to complete the study or required study procedures. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be Progression Free Survival (PFS); defined as the time period from the date of randomization to the date of first radiographical documented progressive disease (PD) or date of death due to any cause, taking the event date that occurs first. The date of PD will be determined by radiographical objective disease (RECIST) measurement.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 30 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |